Body Mass Index and Outcomes after CD19 Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory B-Cell Lymphoma: A Nationwide Registry Study.

Konishi T, Kitamura W, Mizuno S, Yamamoto M, Ishida H, Kitawaki T, Furukawa K, Yoshihara S, Shimoyama T, Iwaki N, Fujii N, Yamamoto G, Kataoka K, Sakaida E, Goto H, Yoshida A, Nakashima Y, Nakazawa H, Umezawa Y, Kim H, Takahashi Y, Atsuta Y, Kato K

Open source

DOI: 10.1016/j.jtct.2026.07.037
Published: 2026 Aug 4
Container: Transplantation and cellular therapy
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.jtct.2026.07.037,
  title = {Body Mass Index and Outcomes after CD19 Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory B-Cell Lymphoma: A Nationwide Registry Study.},
  author = {Konishi T and Kitamura W and Mizuno S and Yamamoto M and Ishida H and Kitawaki T and Furukawa K and Yoshihara S and Shimoyama T and Iwaki N and Fujii N and Yamamoto G and Kataoka K and Sakaida E and Goto H and Yoshida A and Nakashima Y and Nakazawa H and Umezawa Y and Kim H and Takahashi Y and Atsuta Y and Kato K},
  year = {2026},
  journal = {Transplantation and cellular therapy},
  doi = {10.1016/j.jtct.2026.07.037},
  url = {https://doi.org/10.1016/j.jtct.2026.07.037}
}

RIS

TY  - JOUR
TI  - Body Mass Index and Outcomes after CD19 Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory B-Cell Lymphoma: A Nationwide Registry Study.
AU  - Konishi T
AU  - Kitamura W
AU  - Mizuno S
AU  - Yamamoto M
AU  - Ishida H
AU  - Kitawaki T
AU  - Furukawa K
AU  - Yoshihara S
AU  - Shimoyama T
AU  - Iwaki N
AU  - Fujii N
AU  - Yamamoto G
AU  - Kataoka K
AU  - Sakaida E
AU  - Goto H
AU  - Yoshida A
AU  - Nakashima Y
AU  - Nakazawa H
AU  - Umezawa Y
AU  - Kim H
AU  - Takahashi Y
AU  - Atsuta Y
AU  - Kato K
PY  - 2026
JO  - Transplantation and cellular therapy
DO  - 10.1016/j.jtct.2026.07.037
UR  - https://doi.org/10.1016/j.jtct.2026.07.037
ER  -

APA

T, K., W, K., S, M., M, Y., H, I., T, K., K, F., S, Y., T, S., N, I., N, F., G, Y., K, K., E, S., H, G., A, Y., Y, N., H, N., Y, U., H, K., Y, T., Y, A., & K, K. (2026). Body Mass Index and Outcomes after CD19 Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory B-Cell Lymphoma: A Nationwide Registry Study.. Transplantation and cellular therapy. https://doi.org/10.1016/j.jtct.2026.07.037

Source records

pubmed · retrieved 2026-09-26T13:13:45.063Z